Microsoft PowerPoint - Roche IR Event EULAR Final.ppt

More documents

Recommendations

Info

Increased penetration of biologics into mild-tomoderate market segments 10 8 Mild RA 6 4 Patients (%) Moderate RA 402 0 30 20 10 0 2003 2003 2004 2004 2005 2005 2006 2006 Marketed Biologic Products 1-4 Source: Synovate Healthcare 10
Roche in Autoimmune Diseases Building a new therapeutic franchise MabThera Rheumatoid Arthritis • Launched in RA anti-TNFα inadequate responders (IR) in US and EU • Filing for RA in DMARD IR in 2008 Multiple Sclerosis, Lupus, Vasculitis • Phase III in LN, ANCA ass. vasculitis and SLE ongoing Actemra Rheumatoid Arthritis • Filed in Japan • Broad international phase III program ongoing • Global filing in 2007 CellCept Lupus • Phase III in Lupus Nephritis (LN) • Filing 2007 Ocrelizumab Rheumatoid Arthritis, Multiple Sclerosis, Lupus • Phase II trial in RA met primary and secondary endpoints, presented at ACR ’06 • Phase III program in RA initiated • Trials in LN, SLE, and MS to start in 2007 Pamapimod (p38 kinase inhibitor) Rheumatoid Arthritis • In Phase II in RA • Data in 2007 In phase 1 • 6 compounds for autoimmune diseases 7 phase III projects 2 phase II projects 11
Page 2 and 3: Roche Analyst Meeting EULAR 2007 Ba
Page 4 and 5: Introduction Dr. Karl Mahler Head o
Page 6 and 7: Roche’s key therapeutic areas Cur
Page 8 and 9: RA: A very concentrated market 6.00
Page 12 and 13: Actemra: The OPTION trial results P
Page 14 and 15: Elevated IL-6 plays central role in
Page 16 and 17: The OPTION study TOcilizumab Pivota
Page 18 and 19: Demographics Intent-to-treat popula
Page 20 and 21: Results: Efficacy and safety 20
Page 22 and 23: Rapid onset of action with tocilizu
Page 24 and 25: Tocilizumab induces rapid CRP norma
Page 26 and 27: Most frequently reported AEs Incide
Page 28 and 29: Adverse events Consistent with thos
Page 30 and 31: MabThera: Longer-term repeat treatm
Page 32 and 33: Rituximab selectively targets CD20-
Page 34 and 35: Rituximab: Advancing in RA Initial
Page 36 and 37: Inhibition of radiographic progress
Page 38 and 39: Efficacy: Repeat treatment courses
Page 40 and 41: Patient exposure to repeat courses
Page 42 and 43: ACR scores are sustained Repeated c
Page 44 and 45: Consistent time intervals between t
Page 46 and 47: More than 2400 patient-years As of
Page 48 and 49: No increase in infection rates with
Page 50 and 51: IgM RF levels by treatment course o
Page 52 and 53: Rates of serious infection Similar
Page 54 and 55: Roche’s franchise in autoimmune d
Page 56 and 57: Overview of autoimmune disorders IN
Page 58 and 59: Not all patients respond to current
Page 60 and 61:
Major players are active in this ar
Page 62 and 63:
Actemra Potential to become a signi
Page 64 and 65:
Ocrelizumab in autoimmune diseases
Page 66 and 67:
Multiple sclerosis An emerging ther
Page 68 and 69:
Prevalence of MS in Europe ~260,000
Page 70 and 71:
Development hurdles & treatment cha
Page 72 and 73:
Roche in autoimmune disorders Roche
show all

Microsoft PowerPoint - Roche IR Event EULAR Final.ppt

Create successful ePaper yourself

Delete template?

Save as template?